The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications
Open accessAbstract
BACKGROUND: Cholangiocarcinoma (CCA) is clinically heterogeneous; intra and extrahepatic CCA have diverse clinical presentations. Next generation sequencing (NGS) technology may identify the genetic differences between these entities and identify molecular subgroups for targeted therapeutics. METHODS: We describe successful NGS-based testing of 75 CCA patients along with the prognostic and therapeutic implications of findings. Mutation profiling was performed using either a) NGS panel of hotspot regions in 46 cancer-related genes using a 318-chip on Ion PGM Sequencer or b) Illumina HiSeq 2000 sequencing platform for 3,769 exons of 236 cancer-related genes plus 47 introns from 19 genes to an average depth of 1000X. Clinical data was abstracted and correlated with clinical outcome. Patients with targetable mutations were referred to appropriate clinical trials. RESULTS: There were significant differences between intrahepatic (n = 55) and extrahepatic CCA (n = 20) in regard to the nature and frequency of the genetic aberrations (GAs). IDH1 and DNA repair gene alterations occurred more frequently in intrahepatic CCA, while ERBB2 GAs occurred in the extrahepatic group. Commonly occurring GAs in intrahepatic CCA were TP53 (35%), KRAS (24%), ARID1A (20%), IDH1 (18%), MCL1 (16%) and PBRM1 (11%). Most frequent GAs in extrahepatic CCA (n = 20) were TP53 (45%), KRAS (40%), ERBB2 (25%), SMAD4 (25%), FBXW7 (15%) and CDKN2A (15%). In intrahepatic CCA, KRAS, TP53 or MAPK/mTOR GAs were significantly associated with a worse prognosis while FGFR GAs correlated with a relatively indolent disease course. IDH1 GAs did not have any prognostic significance. GAs in the chromatin modulating genes, BAP1 and PBRM1 were associated with bone metastases and worse survival in extrahepatic CCA. Radiologic responses and clinical benefit was noted with EGFR, FGFR, C-met, B-RAF and MEK inhibitors. CONCLUSION: There are significant genetic differences between intra and extrahepatic CCA. NGS can potentially identify disease subsets with distinct prognostic and therapeutic implications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
Valle, J., Wasan, H., Palmer, D. H., Cunningham, D., Anthoney, A., Maraveyas, A., Madhusudan, S., Iveson, T., Hughes, S., Pereira, S. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908721 · Cited by 4,406
Wolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.9984 · Cited by 4,030
Cancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203
Choi, W., Porten, S., Kim, S., Willis, D., Plimack, E. R., Hoffman-Censits, J., Roth, B., Cheng, T., Tran, M., Lee, I.-L., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.009 · Cited by 1,716
Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas
Harbour, J. W., Onken, M. D., Roberson, E. D. O., Duan, S., Cao, L., Worley, L. A., Council, M. L., Matatall, K. A., Helms, C., & Bowcock, A. M. (2010) · Science · doi:10.1126/science.1194472 · Cited by 1,462
Gnirke, A., Melnikov, A., Maguire, J., Rogov, P., LeProust, E. M., Brockman, W., Fennell, T., Giannoukos, G., Fisher, S., Russ, C., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1523 · Cited by 1,433 · cited 1×
“NGS performed by Foundation Medicine used the Illumina Hiseq 2000 Platform for 236 targetable GA’s and the methods for the same have been described previously [13, 14].”
MethodEngelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330
The Epidemiology of Cholangiocarcinoma
Shaib, Y., & El-Serag, H. (2004) · Seminars in Liver Disease · doi:10.1055/s-2004-828889 · Cited by 1,132
New driver mutations in non-small-cell lung cancer
Pao, W., & Girard, N. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70087-5 · Cited by 1,128
Increasing Incidence and Mortality of Primary Intrahepatic Cholangiocarcinoma in the United States
Patel, T. (2001) · Hepatology · doi:10.1053/jhep.2001.25087 · Cited by 1,010
Risk factors for cholangiocarcinoma
Tyson, G. L., & El-Serag, H. B. (2011) · Hepatology · doi:10.1002/hep.24351 · Cited by 956
Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
Bose, R., Kavuri, S. M., Searleman, A. C., Shen, W., Shen, D., Koboldt, D. C., Monsey, J., Goel, N., Aronson, A. B., Li, S., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0349 · Cited by 868
New driver mutations in non-small-cell lung cancer
Tanoue, L. T. (2012) · Yearbook of Pulmonary Disease · doi:10.1016/j.ypdi.2012.01.036 · Cited by 831
Identification of Targetable FGFR Gene Fusions in Diverse Cancers
Wu, Y.-M., Su, F., Kalyana-Sundaram, S., Khazanov, N., Ateeq, B., Cao, X., Lonigro, R. J., Vats, P., Wang, R., Lin, S.-F., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0050 · Cited by 744
Borger, D. R., Tanabe, K. K., Fan, K. C., Lopez, H. U., Fantin, V. R., Straley, K. S., Schenkein, D. P., Hezel, A. F., Ancukiewicz, M., Liebman, H. M., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0386 · Cited by 728
Germline mutations in BAP1 predispose to melanocytic tumors
Wiesner, T., Obenauf, A. C., Murali, R., Fried, I., Griewank, K. G., Ulz, P., Windpassinger, C., Wackernagel, W., Loy, S., Wolf, I., et al. (2011) · Nature Genetics · doi:10.1038/ng.910 · Cited by 725
Jiao, Y., Pawlik, T. M., Anders, R. A., Selaru, F. M., Streppel, M. M., Lucas, D. J., Niknafs, N., Guthrie, V. B., Maitra, A., Argani, P., et al. (2013) · Nature Genetics · doi:10.1038/ng.2813 · Cited by 684
Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?
Shaib, Y. H., Davila, J. A., McGlynn, K., & El-Serag, H. B. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2003.11.030 · Cited by 683
Yoshikawa, D., Ojima, H., Iwasaki, M., Hiraoka, N., Kosuge, T., Kasai, S., Hirohashi, S., & Shibata, T. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604129 · Cited by 404
Borad, M. J., Champion, M. D., Egan, J. B., Liang, W. S., Fonseca, R., Bryce, A. H., McCullough, A. E., Barrett, M. T., Hunt, K., Patel, M. D., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004135 · Cited by 344
Rising trends in cholangiocarcinoma: Is the ICD classification system misleading us?
Khan, S. A., Emadossadaty, S., Ladep, N. G., Thomas, H. C., Elliott, P., Taylor-Robinson, S. D., & Toledano, M. B. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.11.015 · Cited by 290
Tumours associated with BAP1 mutations
Murali, R., Wiesner, T., & Scolyer, R. A. (2013) · Pathology · doi:10.1097/pat.0b013e32835d0efb · Cited by 270
Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma
Kipp, B. R., Voss, J. S., Kerr, S. E., Barr Fritcher, E. G., Graham, R. P., Zhang, L., Highsmith, W. E., Zhang, J., Roberts, L. R., Gores, G. J., et al. (2012) · Human Pathology · doi:10.1016/j.humpath.2011.12.007 · Cited by 244
Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies
Sia, D., Tovar, V, Moeini, A., & Llovet, J. M. (2013) · Oncogene · doi:10.1038/onc.2012.617 · Cited by 235
Kanagal-Shamanna, R., Portier, B. P., Singh, R. R., Routbort, M. J., Aldape, K. D., Handal, B. A., Rahimi, H., Reddy, N. G., Barkoh, B. A., Mishra, B. M., et al. (2014) · Modern Pathology · doi:10.1038/modpathol.2013.122 · Cited by 215
Whole Cancer Genome Sequencing by Next-Generation Methods
Ross, J. S., & Cronin, M. (2011) · American Journal of Clinical Pathology · doi:10.1309/ajcpr1svt1vhugxw · Cited by 164
Bertuccio, P., Bosetti, C., Levi, F., Decarli, A., Negri, E., & Vecchia, C. L. (2013) · Annals of Oncology · doi:10.1093/annonc/mds652 · Cited by 140
Goeppert, B. F., Frauenschuh, L., Renner, M., Roessler, S. K., Stenzinger, A., Klauschen, F., Warth, A., Vogel, M. N., Mehrabi, A., Hafezi, M., et al. (2013) · Modern Pathology · doi:10.1038/modpathol.2013.206 · Cited by 136
Prognostic parameters in uveal melanoma and their association with BAP1 expression
van Essen, T. H., van Pelt, S. I., Versluis, M., Bronkhorst, I. H. G., van Duinen, S. G., Marinkovic, M., Kroes, W. G. M., Ruivenkamp, C. A. L., Shukla, S., de Klein, A., et al. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305047 · Cited by 129
Nakayama, N., Nakayama, K., Yeasmin, S., Ishibashi, M., Katagiri, A., Iida, K., Fukumoto, M., & Miyazaki, K. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604783 · Cited by 125
The Expression of Phospho-AKT, Phospho-mTOR, and PTEN in Extrahepatic Cholangiocarcinoma
Chung, J., Hong, S., Choi, B. Y., Cho, H., Yu, E., & Hewitt, S. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1084 · Cited by 123
Descriptive Epidemiology of Cholangiocarcinoma and Clonorchiasis in Korea
Shin, H., Oh, J., Lim, M. K., Shin, A., Kong, H., Jung, K., Won, Y., Park, S., Park, S., & Hong, S. (2010) · Journal of Korean Medical Science · doi:10.3346/jkms.2010.25.7.1011 · Cited by 122
Roa, I., de Toro, G., Schalper, K. A., de Aretxabala, X., Churi, C. R., & Javle, M. M. (2014) · Europe PMC (PubMed Central) · Cited by 103
Self-citationNeratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer
Bose, P., & Ozer, H. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903305428 · Cited by 96
Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment
Herter-Sprie, G. S., Greulich, H. E., & Wong, K. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00086 · Cited by 95
Molecular characterization of gallbladder cancer using somatic mutation profiling
Javle, M. M., Rashid, A., Churi, C. R., Kar, S., Zuo, M., Eterovic, A. K., Nogueras‐González, G. M., Jankú, F., Shroff, R. T., Aloia, T. A., et al. (2013) · Human Pathology · doi:10.1016/j.humpath.2013.11.001 · Cited by 89
Self-citationHamidi, H., Lu, M., Chau, K., Anderson, L., Fejzo, M., Ginther, C., Linnartz, R., Zubel, A., Slamon, D., & Finn, R. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.475 · Cited by 50
ERBB2 kinase domain mutation in the lung squamous cell carcinoma
Lee, J. W., Soung, Y. H., Kim, S. Y., Nam, S. W., Park, W. S., Wang, Y. P., Jo, K. H., Moon, S. W., Song, S. Y., Lee, J. Y., et al. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.05.026 · Cited by 48
Self-citationSubbiah, I. M., Subbiah, V., Tsimberidou, A. M., Naing, A., Kaseb, A. O., Javle, M. M., Fu, S., Hong, D. S., Piha-Paul, S. A., Wheler, J. J., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.832 · Cited by 35
Self-citationObesity and cholangiocarcinoma
Parsi, M. A. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i4.457 · Cited by 35
Releasing the Block: Setting Differentiation Free with Mutant IDH Inhibitors
Pirozzi, C. J., Reitman, Z. J., & Yan, H. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.04.024 · Cited by 20
Cited by
Cholangiocarcinoma — evolving concepts and therapeutic strategies
Ilyas, S. I., Khan, S. A., Hallemeier, C. L., Kelley, R. K., & Gores, G. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.157 · Cited by 1,626
Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis
Sia, D., Villanueva, A., Friedman, S. L., & Llovet, J. M. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.11.048 · Cited by 1,153
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
Javle, M., Lowery, M., Shroff, R. T., Weiss, K. H., Springfeld, C., Borad, M. J., Ramanathan, R. K., Goyal, L., Sadeghi, S., Macarulla, T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.5009 · Cited by 693
Self-citationNew Horizons for Precision Medicine in Biliary Tract Cancers
Valle, J. W., Lamarca, A., Goyal, L., Barriuso, J., & Zhu, A. X. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0245 · Cited by 626
Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles
Farshidfar, F., Zheng, S., Gingras, M.-C., Newton, Y., Shih, J., Robertson, A. G., Hinoue, T., Hoadley, K. A., Gibb, E. A., Roszik, J., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.033 · Cited by 610
Self-citation
Metadata
- Authors
- Churi, C. R., Shroff, R., Wang, Y., Rashid, A., Kang, H. C., Weatherly, J., Zuo, M., Zinner, R., Hong, D., Meric-Bernstam, F., Janku, F., Crane, C. H., Mishra, L., Vauthey, J.-N., Wolff, R. A., Mills, G., & Javle, M.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-12-23
- Volume
- 9
- Issue
- 12
- Pages
- e115383
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W1974564771
- Cited by
- 450
- References
- 41
- FWCI
- 26.58
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.